• Mary Manoranjani Addanki
• Prakash Katakam
• Shanta Kumari Adiki
• Jessi Dason Vardhanapu
• Prameela Rani Avula

Tetanus toxoid vaccination is primarily used for tetanus prevention. The conventional vaccine for tetanus toxoid is characterised by the limitations of pain, sterility issues, and cold storage. Hence, a pulmonary administered tetanus toxoid (TT) vaccine was fabricated to overcome the limitations of conventional intramuscular vaccines. The goal of this study was to make a dry powder of tetanus toxoid that could be inhaled using maltose and leucine as a vaccine carrier. Additionally, TT dry powder inhalation (DPI) was intended to confer antigenicity and stability. Maltose, leucine and tetanus toxoid were homogenised and centrifuged to obtain the particles of Maltose-leucine-tetanus toxoid (MLTT). Particle size analysis, FTIR, encapsulation efficiency, flocculation, in vitro vaccine release tests, and flow characteristics were all performed on the produced particles. MLTT powder combination remained stable during the process and after storage. FTIR analysis, showed no chemical interactions. The homogenization method produced a powder with the geometrical particle size of the DPI formulation, in the range between 95.6 ± 5.7 nm and 1081.1 ± 10.8 nm which was believed to be appropriate for inhalation. Whereas -27 ± 0.6 mV and 0.496 ± 0.013 were found to be the zeta potential and polydispersity index, respectively. The formation of flocculation of tetanus toxoid with antitoxin as at 20 min confirms the antigenicity of the same. TT was released immediately with 83.2 ± 4.9% within 2 h following the diffusion mechanism. The findings revealed the powder blend’s potential as a dry powder inhalation for delivering TT.

Tetanus toxoid, Maltose, Leucine, Dry powder inhalation, Pulmonary administration, Mucosal vaccine.

"Formulation and Evaluation of Maltose-Leucine-Tetanus Toxoid Dry Powder Inhalation for Pulmonary Delivery", International Journal of Emerging Technologies and Innovative Research (www.jetir.org), ISSN:2349-5162, Vol.6, Issue 5, page no.657-664, May 2019, Available :http://www.jetir.org/papers/JETIR1905P95.pdf

"Formulation and Evaluation of Maltose-Leucine-Tetanus Toxoid Dry Powder Inhalation for Pulmonary Delivery", International Journal of Emerging Technologies and Innovative Research (www.jetir.org | UGC and issn Approved), ISSN:2349-5162, Vol.6, Issue 5, page no. pp657-664, May 2019, Available at : http://www.jetir.org/papers/JETIR1905P95.pdf